Deferasirox-Induced Hyperammonemia in an Adult Patient After Allogeneic Stem Cell Transplantation

Abstract

Get full access to this article

View all access options for this article.

References

Vanorden

Hagemann

. Deferasirox—an oral agent for chronic iron overload. Ann Pharmacother. 2006;40:1110-1117. doi:10.1345/aph.1G566

Martinelli

Goffredo

Falvella

Marano

. Acute hyperammonemia in children under deferasirox treatment: cutting the Gordian knot. Clin Toxicol (Phila). 2019;57:375-377. doi:10.1080/15563650.2018.1523425

Marano

Bottaro

Goffredo

, et al. Deferasirox-induced serious adverse reaction in a pediatric patient: pharmacokinetic and pharmacogenetic analysis. Eur J Clin Pharmacol. 2016;72:247-248. doi:10.1007/s00228-015-1956-2

Arber

Orazi

Hasserjian

, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391-2405. doi:10.1182/blood-2016-03-643544

LaBuzetta

Yao

Bourque

Zivin

. Adult nonhepatic hyperammonemia: a case report and differential diagnosis Am J Med. 2010;123:885-891. doi:10.1016/j.amjmed.2010.02.029

Naranjo

Busto

Sellers

, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245. doi:10.1038/clpt.1981.154

Bommakanti

McKell

. Metabolic encephalopathy in a sickle cell patient taking deferasirox. Am J Respir Crit Care Med. 2020;201:A6914.

Serafinelli

Martinelli

Pisani

, et al. Severe hyperammonemia without liver failure induced by deferasirox: a biochemical conundrum. Toxicol Lett. 2017;280:S318. doi:10.1016/j.toxlet.2017.08.060